Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 30% Share Price Plunge Could Signal Some Risk

To the annoyance of some shareholders, Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) shares are down a considerable 30% in the last month, which continues a horrid run for the company. The

Simply Wall StApr 17 06:10

Olin Biotech (688319.SH): The company's products have been exported in small quantities to Pakistan

Gelonghui, April 10 | Olin Biotech (688319.SH) said on the investor interactive platform that the company's products have been exported in small quantities to Pakistan. The human vaccine development cycle is long and the investment is high. In order to maintain continuous competitiveness, the company will steadily advance progress in the research pipeline according to the plan. The country attaches great importance to the human vaccine industry. In recent years, it has introduced a series of policies to support the development of the vaccine industry.

Gelonghui FinanceApr 10 17:24

Olin Biotech (688319.SH): Not involved in artificial intelligence-related technology

Gelonghui, March 19 | Olin Biotech (688319.SH) said on the investor interactive platform that the company focuses on the R&D, production and sales of human vaccines. The pilot platform mainly focuses on the development and utilization of vaccines, and does not yet involve artificial intelligence-related technology.

Gelonghui FinanceMar 19 18:55

Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has had a rough three months with its share price down 45%. But if you pay close attention, you might find that its key financial indicators look qui

Simply Wall StMar 4 13:59

Olin Biotech (688319.SH) performance report: 2023 net profit of 174.14,400 yuan, a year-on-year decrease of 34.49%

Gelonghui, Feb. 27丨Olin Biotech (688319.SH) announced its 2023 annual results report. During the reporting period, the company achieved operating income of 496.1187 million yuan, a year-on-year decrease of 9.38%; realized net profit attributable to owners of the parent company was 17.4,104 million yuan, a year-on-year decrease of 34.49%; and realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 3.205,500 yuan, an increase of 344.77% year on year.

Gelonghui FinanceFeb 27 18:31

Express News | Olin Biotech: Withdrawal of AC-HiB Combined Vaccine Drug Registration Application

BreakingsFeb 1 18:05